SCHEMBL48546

SCHEMBL48546

Cc1nc(N)sc1-c1cc(Cl)c(S(=O)(=O)N(C)C)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 3/20 0.36
PKM P14618 1/20 0.36
RCE1 Q9Y256 1/20 0.36
PIK3CA P42336 2/20 0.36
PIK3CG P48736 2/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CB P42338 1/20 0.36
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
GAA P10253 2/20 0.34
NMT1 P30419 1/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
HSD17B10 Q99714 3/20 0.33
LMNA P02545 3/20 0.33
MAPT P10636 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
HPGD P15428 2/20 0.33
MAPK1 P28482 2/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48967 0.85 MEN1 (0.41) ALDH1A1KDM4EPKMRCE1PIK3CA
SCHEMBL48853 0.78 PIK3CG (0.62) PIK3CAPIK3CGPIK3CDPIK3CBPIK3C3
SCHEMBL48399 0.76 PIK3CD (0.44) ALDH1A1KDM4EPKMPIK3CAPIK3CG
SCHEMBL1786529 0.73 PIK3CD (0.63) ALDH1A1KDM4EPKMRCE1PIK3CA
SCHEMBL1891948 0.72 NOS1 (0.45) ALDH1A1KDM4EPIK3CGMEN1KMT2A
Bromide SCHEMBL1885215 0.71 NOS1 (0.43) ALDH1A1KDM4EPIK3CGMEN1KMT2A
SCHEMBL48627 0.70 PIK3CD (0.51) ALDH1A1KDM4EPKMRCE1PIK3CA
SCHEMBL2032047 0.68 NOS1 (0.43) ALDH1A1MEN1KMT2AGAAHSD17B10
SCHEMBL925400 0.67 PIK3CB (0.43) PIK3CAPIK3CGPIK3CDPIK3CBPIK3C3
SCHEMBL26479577 0.67 KDM4E (0.49) ALDH1A1KDM4EPKMRCE1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311818-B1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug NOVARTIS AG (CH) 2013-01-16 EP disclosed
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
EP-2311818-A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug Novartis AG (CH) 2011-04-20 EP disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors NOVARTIS AG (CH) 2005-06-02 US disclosed
EP-1480962-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS Novartis AG (CH) 2004-12-01 EP disclosed
WO-2003072557-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS PIK3CA, PIK3R5, PIP5K1B ALDH1A1 3271/4885KDM4E 967/4885PKM 621/4885
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors PIK3CA, PIK3R5, PIP5K1B ALDH1A1 3271/4885KDM4E 967/4885PKM 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.